CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to IVBXF

Aflibercept Ophthalmic

Phase 3
Innovent Biologics Inc/ADR (IVBXF)

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Feb '27
IVBXFPhase 3

Aflibercept Ophthalmic Phase 3 Est. Readout

Aflibercept Ophthalmic
Feb 2027~
CT.gov
00%
Competitive Landscape

1 competitor in Neovascular Age-related Macular Degeneration

View Full Landscape
Drug Information

Target Indication

Neovascular Age-related Macular Degeneration

Clinical Trial

NCT05972473

Last updated: 10/3/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.